Pathology of C3 Glomerulopathy

키워드

참고문헌 (66)

1. Smith RJH, "C3 glomerulopathy-understanding a rare complementdriven renal disease", Nat Rev Nephrol, 15, pp.129~143 (2019)
2. Baines AC, "Complementopathies", Blood Rev, 31, pp.213~223 (2017)
3. Khalighi MA, "Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy", Clin Kidney J, 9, pp.397~402 (2016)
4. Ito N, "C3 glomerulopathy and current dilemmas", Clin Exp Nephrol, 21, pp.541~551 (2017)
5. Pickering MC, "C3 glomerulopathy : consensus report", Kidney Int, 84, pp.1079~1089 (2013)
6. Alchi B, "Membranoproliferative glomerulonephritis", Pediatr Nephrol, 25, pp.1409~1418 (2010)
7. Levy M, "Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits(Type I MPGN)", Clin Immunol Immunopathol, 10, pp.477~492 (1978)
8. Habib R, "Dense deposit disease : a variant of membranoproliferative glomerulonephritis", Kidney Int, 7, pp.204~215 (1975)
9. Burkholder PM, "Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study", Lab Invest, 23, pp.459~479 (1970)
10. Strife CF, "Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane", Clin Nephrol, 7, pp.65~72 (1977)
11. Anders D, "Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections", Virchows Arch A Pathol Anat Histol, 376, pp.1~19 (1977)
12. Nasr SH, "Dense deposit disease : clinicopathologic study of 32 pediatric and adult patients", Clin J Am Soc Nephrol, 4, pp.22~32 (2009)
13. Walker PD, "Dense deposit disease is not a membranoproliferative glomerulonephritis", Mod Pathol, 20, pp.605~616 (2007)
14. Belgiojoso GB, "Immunofluorescence patterns in chronic membranoproliferative glomerulonephritis(MPGN)", Clin Nephrol, 6, pp.303~310 (1976)
15. Pickering RJ, "Chronic glomerulonephritis associated with low serum complement activity(chronic hypocomplementemic glomerulonephritis)", Medicine(Baltimore), 49, pp.207~226 (1970)
16. Fakhouri F, "C3 glomerulopathy : a new classification", Nat Rev Nephrol, 6, pp.494~499 (2010)
17. Noris M, "Overview of complement activation and regulation", Semin Nephrol, 33, pp.479~492 (2013)
18. Bomback AS, "Complement-Mediated Glomerular Diseases : A Tale of 3 Pathways", Kidney Int Rep, 1, pp.148~155 (2016)
19. Nilsson B, "The tick-over theory revisited : Is C3 a contact-activated protein", Immunobiology, 217, pp.1106~1110 (2012)
20. Wong EKS, "Diseases of complement dysregulationan overview", Semin Immunopathol, 40, pp.49~64 (2018)
21. Spitzer RE, "Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis", Clin Immunol Immunopathol, 57, pp.10~18 (1990)
22. Jozsi M, "Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome", Immunol Lett, 160, pp.163~171 (2014)
23. Paixao-Cavalcante D, "Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation", Kidney Int, 82, pp.1084~1092 (2012)
24. Ito S, "Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor", Immunology, 68, pp.449~452 (1989)
25. Zhang Y, "Soluble CR1 therapy improves complement regulation in C3 glomerulopathy", J Am Soc Nephrol, 24, pp.1820~1829 (2013)
26. Corvillo F, "Nephritic Factors : An Overview of Classification, Diagnostic Tools and Clinical Associations", Front Immunol, 10, pp.886~ (2019)
27. Marinozzi MC, "C5 nephritic factors drive the biological phenotype of C3 glomerulopathies", Kidney Int, 92, pp.1232~1241 (2017)
28. Zhang Y, "C4 Nephritic Factors in C3 Glomerulopathy : A Case Series", Am J Kidney Dis, 70, pp.834~843 (2017)
29. Ravindran A, "C3Glomerulopathy : Ten Years' Experience at Mayo Clinic", Mayo Clin Proc, 93, pp.991~1008 (2018)
30. Michels M, "Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy", Front Immunol, 10, pp.1350~ (2019)
31. Blanc C, "Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome : one target, two diseases", J Immunol, 194, pp.5129~5138 (2015)
32. Marinozzi MC, "Anti-Factor B and Anti-C3b Autoantibodies in C3Glomerulopathy and Ig-Associated Membranoproliferative GN", J Am Soc Nephrol, 28, pp.1603~1613 (2017)
33. Goicoechea de Jorge E, "Dimerization of complement factor H-related proteins modulates complement activation in vivo", Proc Natl Acad Sci U S A, 110, pp.4685~4690 (2013)
34. Martinez-Barricarte R, "Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation", J Clin Invest, 120, pp.3702~3712 (2010)
35. Pickering M, "Complement and glomerular disease : new insights", Curr Opin Nephrol Hypertens, 20, pp.271~277 (2011)
36. Ravindran A, "C3 glomerulopathy associated with monoclonal Ig is a distinct subtype", Kidney Int, 94, pp.178~186 (2018)
37. Sethi S, "The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases", J Am Soc Nephrol, 29, pp.1810~1823 (2018)
38. Sethi S, "Spectrum of manifestations of monoclonal gammopathy-associated renal lesions", Curr Opin Nephrol Hypertens, 25, pp.127~137 (2016)
39. Hou J, "Toward a working definition of C3 glomerulopathy by immunofluorescence", Kidney Int, 85, pp.450~456 (2014)
40. Yagi K, "Clinicopathologic features, outcome, and therapeutic interventions in four children with isolated C3 mesangial proliferative glomerulonephritis", Pediatr Nephrol, 20, pp.1273~1278 (2005)
41. Cook HT, "C3 glomerulopathy", F1000Res, 6, pp.248~ (2017)
42. Servais A, "Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3glomerulopathies", Kidney Int, 82, pp.454~464 (2012)
43. Viswanathan GK, "Clinico-pathologic spectrum of C3 glomerulopathyan Indian experience", Diagn Pathol, 10, pp.6~ (2015)
44. Ravindran A, "C3 glomerulonephritis with a severe crescentic phenotype", Pediatr Nephrol, 32, pp.1625~1633 (2017)
45. Prema KSJ, "Dense deposit disease : a greatly increased biopsy incidence in India versus the USA", Clin Kidney J, 12, pp.476~482 (2019)
46. 박세진, "Dense Deposit Disease in Korean Children: A Multicenter Clinicopathologic Study", Journal of Korean Medical Science, 27(10), pp.1215~1221 (2012), 대한의학회
47. Sethi S, "Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease", Kidney Int, 88, pp.1449~1450 (2015)
48. Cook HT, "Histopathology of MPGN and C3 glomerulopathies", Nat Rev Nephrol, 11, pp.14~22 (2015)
49. Sethi S, "Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement", Clin J Am Soc Nephrol, 6, pp.1009~1017 (2011)
50. Bridoux F, "Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy : a fortuitous association", Clin J Am Soc Nephrol, 6, pp.2165~2174 (2011)
51. Hawf ield A, "Alternative pathway dysfunction in kidney disease : a case report and review of dense deposit disease and C3 glomerulopathy", Am J Kidney Dis, 61, pp.828~831 (2013)
52. Strife CF, "Crescentic glomerulonephritis in childhood : acute nonproliferative glomerulitis versus dense deposit disease", Am J Kidney Dis, 41, pp.897~ (2003)[DOI]
53. Churg J, "Identification of dense deposit disease : a report for the International Study of Kidney Diseases in Children", Arch Pathol Lab Med, 103, pp.67~72 (1979)
54. Medjeral-Thomas NR, "C3 glomerulopathy : clinicopathologic features and predictors of outcome", Clin J Am Soc Nephrol, 9, pp.46~53 (2014)
55. Sethi S, "C4d as a Diagnostic Tool in Proliferative GN", J Am Soc Nephrol, 26, pp.2852~2859 (2015)
56. Goodship TH, "Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference", Kidney Int, 91, pp.539~551 (2017)
57. Sethi S, "Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement", Kidney Int, 83, pp.293~299 (2013)
58. Kanjanabuch T, "An update on acute postinfectious glomerulonephritis worldwide", Nat Rev Nephrol, 5, pp.259~269 (2009)
59. Fish AJ, "Epidemic acute glomerulonephritis associated with type 49 streptococcal pyoderma. II. Correlative study of light, immunofluorescent and electron microscopic findings", Am J Med, 48, pp.28~39 (1970)
60. Sethi S, "C3glomerulonephritis : clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up", Kidney Int, 82, pp.465~473 (2012)
61. Sandhu G, "C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis", Am J Kidney Dis, 60, pp.1039~1043 (2012)
62. Vernon KA, "Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency", Am J Kidney Dis, 60, pp.121~125 (2012)
63. Suga K, "A case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency", Pediatr Nephrol, 25, pp.1547~1550 (2010)
64. Prasto J, "Streptococcal infection as possible trigger for dense deposit disease(C3glomerulopathy)", Eur J Pediatr, 173, pp.767~772 (2014)
65. Sawanobori E, "A prolonged course of Group A streptococcus-associated nephritis : a mild case of dense deposit disease(DDD)", Clin Nephrol, 71, pp.703~707 (2009)
66. Okabe M, "A case of idiopathic membranoproliferative glomerulonephritis with a transient glomerular deposition of nephritis-associated plasmin receptor antigen", Clin Exp Nephrol, 16, pp.337~341 (2012)

관련 논문AI추천